Literature DB >> 8879376

Patient-controlled analgesia with oral methadone in cancer pain: preliminary report.

S Mercadante1, M Sapio, R Serretta, M Caligara.   

Abstract

BACKGROUND: Methadone is a very useful drug in cancer pain because of its low cost, lack of active metabolites, high oral availability, and the rapid onset of its analgesic effect. It seems to be well tolerated in patients with difficult pain syndromes who are receiving high doses of opioids, and it may deter the development of tolerance, but a high individual variation in terminal elimination half-life can result in different rates and extents of drug accumulation. For this reason, oral patient-controlled analgesia with methadone was used in 24 advanced-disease patients with pain. PATIENTS AND METHODS: A regimen of self-administered oral methadone at fixed doses and flexible patient-controlled dosage intervals to achieve adequate analgesia, while avoiding toxic effects of methadone accumulation, was used in 24 patients requiring opioid therapy. After a priming period of three days with fixed doses of 3-5 mg three times a day for naïve patients and 50% of the morphine equivalent of methadone in patients switched from morphine, patients and relatives were instructed to maintain the night-time dose and to administer a second dose when the pain recurred. When more than four doses of methadone a day were used, an increase of the dosage was prescribed. Continuous pain assessment and monitoring of symptoms were offered.
RESULTS: The majority of patients achieved good pain relief until death, and three were switched to very low doses of subcutaneous morphine in their final days. The methadone escalation index was about 2% a day, with a mean dosage increase of 0.3 mg a day for an average of 60 days of treatment at doses ranging from 9 to 80 mg. The plasma concentration in 14 patients ranged from 0.013 to 0.273 mcg/ml with dosages of 20-80 mg during chronic treatment. A mean of 2.4 doses a day was reported, including the fixed night-time dose. The extent of side effects was considered acceptable.
CONCLUSION: Patient-administered analgesia with oral methadone appears to be a simple, cheap and relatively safe technique for controlling cancer pain, permitting individualization by the patient him- or herself and avoiding the risk of accumulation. Continuous assessment is necessary.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879376     DOI: 10.1093/oxfordjournals.annonc.a010679

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  8 in total

Review 1.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 2.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Oxford House Residents' Attitudes Toward Medication Assisted Treatment Use in Fellow Residents.

Authors:  John M Majer; Christopher Beasley; Emily Stecker; Ted J Bobak; Joshua Norris; Hai Minh Nguyen; Maisie Ogata; Jordana Siegel; Elzbieta Wiedbusch; Isabel Dovale; Noah Gelfman; Sarah Callahan; Leonard A Jason
Journal:  Community Ment Health J       Date:  2018-01-04

4.  Evaluation of the analgesic effect of subcutaneous methadone after cesarean section.

Authors:  Mitra Jabalameli; Forough Kalantari
Journal:  Adv Biomed Res       Date:  2014-09-23

5.  Opioid therapy in patients with a history of substance abuse.

Authors:  Steven D Passik; Kenneth L Kirsh
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies.

Authors:  Joao P De Aquino; Suprit Parida; Victor J Avila-Quintero; Jose Flores; Peggy Compton; Thomas Hickey; Oscar Gómez; Mehmet Sofuoglu
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

Review 7.  Pain management in the opioid-dependent patient.

Authors:  J Streltzer
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 8.081

8.  Methadone as First-line Opioid for the Management of Cancer Pain.

Authors:  Sebastiano Mercadante; Claudio Adile; Patrizia Ferrera; Maria Caterina Pallotti; Marianna Ricci; Giuseppe Bonanno; Alessandra Casuccio
Journal:  Oncologist       Date:  2022-04-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.